Business
HLS Therapeutics welcomes both CADTH's recommendation to reimburse Vascepa® (icosapent ethyl) for patients with established cardiovascular disease and PMPRB's notification on its introductory price
HLS Therapeutics welcomes both CADTH's recommendation to reimburse Vascepa® (icosapen...
About this update from Hls Therapeutics, Inc.
[{"type":"text","content":"\n\n\n\nHLS Therapeutics welcomes both CADTH's recommendation to reimburse Vascepa® (icosapent ethyl) for patients with established cardiovascular disease and PMPRB's notification on its introductory price\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n.prngen2{\nBORDER-TOP:black 0pt; BORDER-RIGHT:black 0pt; VERTICAL-ALIGN: TOP; BORDER-BOTTOM:black 0pt; TEXT-ALIGN: LEFT; PADDING-LEFT:0.50em; BORDER-LEFT:black 0pt; PADDING-RIGHT:0.50em\n}\n.prnbcc{\nBORDER-TOP:0pt solid; BORDER-RIGHT:0pt solid; BORDER-COLLAPSE: COLLAPSE; BORDER-BOTTOM:0pt solid; BORDER-LEFT:0pt solid\n}\n\n\n\n\n\n\n\nCanada NewsWire\nTORONTO, July 20, 2020\n\n\n\nCADTH recommends Vascepa be reimbursed for patients with established cardiovascular disease under certain conditions. PMPRB notifies HLS that following PMPRB's review, Vascepa's introductory price submission did not trigger the pricing investigation criteria.  HLS reaffirms its peak-year sales forecast for Vascepa. HLS management to hold investor update conference call with accompanying slides today at 5:30 p.m. EDT. TORONTO, July 20, 2020 /CNW/ - HLS Therapeutics Inc. (\"HLS\" or the \"Company\") (TSX: HLS), a specialty pharmaceutical company focusing on central nervous system and cardiovascular markets welcomes the recent recommendation by the Canadian Agency for Drugs and Technologies in Health (\"CADTH\") that Vascepa be reimbursed by participating public drug plans for statin-treated patients with established cardiovascular diseases and elevated triglycerides. \nHaving worked diligently to ensure an appropriate introductory price, HLS also received notification by the PMPRB that, further to its review, Vascepa's price did not trigger the investigation criteria for excessive pricing.\nMany patients may benefit as this recommendation helps make available a new treatment option\n\"We are very pleased to see Vascepa's benefit be recognized as a relevant agent to reduce the risk of major adverse cardiovascular events for patients that have documented cardiovascular disease. HLS, with the support of leading physicians, medical societies and other ...